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Cardiopulmonary resuscitation (CPR) is often 
considered a contraindication to thrombolytic 
therapy for acute myocardial infarction. Df 706 
patients involved in the first 3 Thrombolysis and 
Angioplasty in Myocardial Infarction trials of iyt- 
ic therapy for acute infarction, 59 patients re- 
quired <lO minutes of CPR before receiving iytic 
therapy (CPR >lO minutes was an exclusion of 
the trials) or required CPR within 6 hours of 
treatment. The patients receiving CPR were sim- 
ilar to the remainder of the group with respect to 
baseline demographics. The indication for CPR 
was usually ventricular fibrillation (73%) or ven- 
tricular tachycardia (24%). The median duration 
of CPR was 1 minute, with twenty-fifth and sev- 
enty-fifth percentiles of 1 and 5 minutes, respec- 
tively. The median number of cardioversions/de- 
fibrillations performed was 2 (twenty-fifth and 
seventy-fifth percentiles of 1 and 3 minutes, re- 
spectively). Patients receiving CPR were more 
likely to have anterior infarctions (66 vs 39%), 
the left anterior descending artery as the infarct- 
related artery (63 vs 36%) and lower ejection 
fractions on the initial ventriculogram (46 f 11 
vs 52 f 12%) than those not receiving CPR. in- 
hospltal mortality was 12 vs 6% with most 
deaths due to pump failure (57%) or arrhythmia 
(29%) in the CPR group and pump failure (38%) 
or reinfarction (25%) in the non-CPR group. At 
7 day follow-up the CPR group had a significant 
increase in ejection fraction (+5 f 9%) com- 
pared with no change in non-CPR group. There 
were no bleeding complications directly attribut- 
ed to CPR. In particular, the decrease in hemato- 
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crit (median 11) and need for transfusion (37 vs 
32%) were the same in both groups. in addition, 
the CPR group did not spend more days in the 
cardiac care unit or in hospital than the non-CPR 
iwow 
In conclusion, patients who have received 
CPR for <lo minutes had no additional compli- 
cations attributable to thrombolytic therapy 
(95% confidence interval 0 to 5%). Therefore, 
CPR, especially of short duration, should not be 
considered a contraindication to lytic treatment. 
In addition, our results suggest that patients re- 
quiring CPR during acute infarction constitute a 
high-risk subgroup which may particularly bene- 
fit from receiving thrombolytic therapy. 
(Am1 Cardiol 1991;68:1015-1019) 
C 
ardiopulmonary resuscitation (CPR) is often 
cited as a contraindication to thrombolytic 
therapy.‘s2 In patients with acute myocardial 
infarction the need for defibrillation, precordial thump, 
and a short period of chest compression is common, 
with the reported incidence of early cardiac arrest in 
clinical trials of thrombolytic therapy ranging from 10 
to 16%~~~~ The recommendation to exclude such pa- 
tients from receiving therapy is not based on firm data 
and no studies that specifically address this question 
have been published. Because patients requiring CPR 
are at high risk with conservative therapy,6 they poten- 
tially have the most to gain from thrombolytic treat- 
ment and therefore should not be excluded without 
good reason. To investigate this issue, we evaluated pa- 
tients enrolled in the Thrombolysis and Angioplasty in 
Myocardial Infarction trials who had received CPR be- 
fore or early in the course of therapy compared with 
patients who had not received CPR. 
METHOD5 
The study population included 708 consecutive pa- 
tients entered into the first 3 Thrombolysis and Angio- 
plasty in Myocardial Infarction trials.7-9 Patients pre- 
senting within 6 hours of the onset of chest pain with 
electrocardiographic changes consistent with an acute 
myocardial infarction (> I mm ST elevation in 2 con- 
tiguous leads) were eligible for study. Exclusion criteria 
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TABLE I Baseline Demographics 
All Prolonged No 
CPR CPR CPR 
(n = 59) (n = 22) (n = 649) 
Age (years) 55 (46-60) 58 (45-61) 57 (49-65) 
Gender: m/f 47 (80)/12 (20) 18 (82)/4 (18) 518 (80)/131 (20) 
Race 
White 52 (88) 20 (91) 602 (93) 
Black 5 (8) 2 (9) 38 (6) 
Indian 1 (2) 0 (0) 4 (1) 
Asiatic 1 (2) 0 (0) 0 (0) 
Other 0 (0) 0 (0) 5 (1) 
Risk factors 
Hypertension* 29 (49) 12 (55) 261 (40) 
Diabetes mellitus 11 (19) 6 (27) 95 (15) 
Hyperlipidemiat 9 (15) 4 (18) 67 (10) 
Cigarette smoking 46 (78) 12 (55) 488 (75) 
Family history of coronary disease 31 (53) 8 (36) 288 (44) 
Time to treatment (min) 160 (136-210) 151(131-191) 175 (126-220) 
*Hypertension defined as any previous history of hypertension diagnosed by a physician and treated with medications, diet or exercise. 
tHyperlipidemia defined as a history of hyperlipidemia diagnosed by a physician or a history of a blood cholesterol > 200 mgldl. 
Values in parentheses indicate percentage except for age and time to treatment where they indicate 25th to 75th percentiles. 
CPR = cardiopulmonary resuscitation. 
were age >75 years, history of recent stroke, surgery or 
trauma, predisposition for bleeding, uncontrolled hyper- 
tension (diastolic blood pressure >120 mm Hg), previ- 
ous coronary artery bypass surgery, previous Q-wave 
infarction in the same vascular distribution and cardio- 
genie shock (systolic blood pressure <85 mm Hg unre- 
sponsive to administration of fluid). In addition, CPR 
for > 10 minutes was an exclusion criterion. Of the total 
population of 708 patients, 59 required CPR for <lO 
minutes before receiving lytic therapy or had CPR dur- 
ing or soon after lytic therapy was started (<6 hours). 
These patients constitute the subpopulation studied. 
In phase 1 of the Thrombolysis and Angioplasty in 
Myocardial Infarction trials,7 patients received 150 mg 
of intravenous tissue plasminogen activator over 6 to 8 
hours. Cardiac catheterization was performed 90 min- 
utes after initiation of lytic therapy, with 5,000 U of 
intravenous heparin administered after arterial access 
was attained. Patients with patent arteries amenable to 
angioplasty were then randomized to immediate versus 
elective angioplasty 7 to 10 days later. Patients with 
occluded arteries underwent immediate angioplasty in 
an attempt to restore patency. Repeat catheterization 
was performed in all patients at 7 days. 
In phase 2,8 patients were treated with 1 of 5 regi- 
mens combining various doses of intravenous tissue 
plasminogen activator (1 mg/kg or 25 mg) and uroki- 
nase (0.5 to 2.0 million U). Patients were otherwise 
treated as in phase 1 except that acute angioplasty was 
only performed for occluded vessels. 
In phase 3,9 patients were randomized to receive ei- 
ther a combination of tissue plasminogen activator ( 1.5 
mg/kg over 4 hours) with 10,000 U of heparin or tissue 
plasminogen activator alone. Otherwise treatment was 
the same as in phase 2. 
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After thrombolytic therapy all patients had similar 
management, which included the use of anticoagulation 
with heparin to maintain the activated partial thrombo- 
plastin time 1.5 to 2.0 times the control level for 224 
hours, aspirin 325 mg/day, 1 mg/kg bolus dose of lido- 
Caine or a 225 mg loading dose followed by 2 to 4 
mg/min for the first 24 hours, and diltiazem 30 to 90 
mg every 6 to 8 hours, The use of nitroglycerin was at 
the discretion of the investigator, whereas the use of @ 
blockers was prohibited unless specifically required to 
treat supraventricular tachycardia, hypertension or an- 
gina. 
CPR was defined as an intervention performed in 
response to a change in rhythm to ventricular fibrilla- 
tion, ventricular tachycardia with hemodynamic insta- 
bility, asystole, or electromechanical dissociation, and 
included precordial thump, cardioversion or defibrilla- 
tion, or chest compressions. Because many patients only 
required 1 or 2 defibrillations, data for patients requir- 
ing more extensive CPR than defibrillation only were 
analyzed separately (prolonged CPR group). Treat- 
ment with antiarrhythmic or vasopressor medications 
alone was not included. 
Baseline characteristics and clinical outcomes were 
collected prospectively by trained research nurses using 
previously described definitions.7-9 General bleeding 
complications were similarly characterized. Data on 
days in the cardiac care unit and total days hospitalized 
are not available for patients in phase 1. All routinely 
collected variables were verified by primary source doc- 
umentation by a second trained nurse. Specific details 
and complications of CPR were collected retrospective- 
ly by the same research nurses on supplemental data 
forms. In some patients initially seen in small commu- 
nity hospitals, details of CPR are incomplete. 
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TABLE II Details of Cardiopulmonary Resuscitation (n = 59) 
No. of 
Pts. f%) 





Number of cardioversions/defibriIlations 
Median (25th-75th percentiles) 
Maximal energy delivered (J) 













Duration of CPR (min) 

















Numbers in parentheses indicate percentages unless otherwise specified. 
CPR = cardiopulmonary resuscitaton. 
All data are described with either percentiles for 
continuous variables or percentages for discrete vari- 
ables, except for ejection fraction which is expressed as 
mean f standard deviation. The Wilcoxon rank-sum 
test was used to test comparisons for continuous vari- 
ables, whereas discrete data were analyzed using Fish- 
er’s exact test or the chi-square test. A p value <0.05 
was considered statistically significant. 
RESULTS 
Of 708 patients entered into the trials, 59 (8%) had 
a cardiac arrest. Thirty-seven of these patients required 
only defibrillation and 22 required more extensive re- 
suscitation (prolonged CPR group). There were no sig- 
nificant differences between the CPR and non-CPR 
groups in many baseline characteristics including gen- 
der, the presence of risk factors for coronary artery dis- 
ease or time until treatment (Table I). The CPR group 
was slightly younger and had slightly fewer white pa- 
tients. The subpopulation of patients with prolonged 
CPR was also similar to the control population in base- 
line characteristics. Details of CPR are listed in Table 
II. 
Patients who received CPR were more likely to have 
an anterior myocardial infarction (66 vs 39%) and to 
have left anterior descending artery as the infarct-relat- 
ed artery (63 vs 38%) (Table III). There were no sig- 
nificant differences in the number of diseased vessels, 
infarct vessel patency as assessed by Thrombolysis in 
Myocardial Infarction flow grade, or in the percentage 
TABLE Ill Initial Catheterization Results 
All CPR Prolonged CPR No CPR 
(n = 59) (n = 22) (n = 649) 
Infarct coronary artery 
Left anterior descending 35 (63)* 14 (74H 240 (38) 
Circumflex 5 (9) 0 (0) 84 (13) 
Right 16 (29) 5 (26) 308 (48) 
Left main 0 (0) 0 (0) 1 (0.2) 
Graft 0 (0) 0 (0) 3 (0.5) 
Infarct location 
Anterior 39 (66)* 17 (77H 250 (39) 
Inferior 20 (34) 5 (23) 395 (61) 
TIMI flow$ 
0 11 (20) 4 (21) 139 (22) 
1 3 (51 2 (11) 44 (7) 
2 18 (33) 9 (47) 104 (16) 
3 23 (42) 4 (21) 347 (55) 
Acute angioplasty 24 (43) 11 (58) 273 (42) 
Arteries > 75% diameter stenosis 
0 12 (20) 4 (181 82 (13) 
1 38 (64) 15 (68) 383 (60) 
2 8 (14) 3 114) 122 (19) 
3 1 (2) 0 (0) 55 (9) 
Arteries > 50% diameter stenosis 
0 5 (8) 3 (14) 39 (6) 
1 33 (56) 13 (59) 306 (48) 
2 16 (27) 4 (18) 179 (28) 
3 5 (8) 2 (9) 118 (18) 
Ejection fraction at 46+11* 43112-t 52 -+ 12 
acute catheterization 
*p value <0.05 between all CPR and no CPR groups. 
tp value ~0.05 between prolonged CPR and no CPR. 
Wow determined by arteriography 90 minutes after initiation of lytic therapy. 
Numbers in parentheses indicate percentages. 
CPR = cardiopulmonary resuscitation, TIMI = Thrombolysisin Myocardial Infarction 
trial. 
TABLE IV Mortality 
All CPR No CPR 
(n = 59) (n = 649) 
Mortality 
Death day 1 
Death day 2-7 
Death day > 7 

































Except for the first line, numbers in parentheses indicate percentages calcul#ited 
from the number of patients who died. 
CPR = cardiopulmonary resuscitation. 
of patients treated with acute angioplasty. The patients 
with prolonged CPR also had a preponderance of ante- 
rior infarctions (77%) and left anterior descending ar- 
tery lesions (74%). The baseline ejection fraction was 
lower in the CPR group as expected, given the greater 
proportion of anterior infarcts. 
The in-hospital mortality was somewhat higher in 
the CPR group, and the prolonged CPR group had a 
higher mortality rate than the non-CPR group (32 vs 
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TABLE V Hospital Course 
All CPR Prolonged CPR No CPR 
(n = 59) (n = 22) (n = 649) 
Reocclusion 6 (11) 3 (17) 79 (13) 
Subsequent cardiac arrest* a (14) 5 (23)t 51 (08) 
Sustained hypotension 13 (22) a (36)t 102 (16) 
Pulmonary edema 15 (25)$ 7 (32)t 73 (11) 
Congestive heart failure 10 (17) 3 (14) 68 (11) 
Stroke 0 (0) 0 (0) 13 (2) 
Coma 4 (07) 4 (ia)t 13 (2) 
Change in ejection fractions +5 -c 9t +4 r 8 029 
(n = 33) (n = 10) (n = 444) 
‘CPR after admission to the hospital. 
tpvahx <0.05 behveen prolon 
k 
CPR and noCPR. 
t value <0.05 bAween all CP and no CPR. 
$batients with repeat ventrculogram beforedischarge. 
CPR = cardlopulmanary rwscitatlon. 
6%, p = 0.0001). All of the deaths in the CPR group 
occurred in the group with prolonged CPR. In both 
groups, many of the deaths occurred (luring the first 
hospital day (Table IV). The most common cause of 
death in both groups was pump failure. 
The hospital course in the total CPR and non-CPR 
groups was similar with respect to reocclusion, subse- 
quent cardiac arrest, sustained hypotension, congestive 
heart failure, stroke or coma (Table V). The prolonged 
CPR group had a greater incidence of subsequent car- 
diac arrests, sustained hypotension, pulmonary edema 
and coma. Both the total CPR and prolonged CPR 
groups had an increase in ejection fraction on the pre- 
discharge ventriculogram (5 and 4%, respectively) com- 
pared with no increase in the non-CPR group. 
There were no direct complications of CPR noted. 
Specifically, there were no cases of pericardial tampon- 
ade, rib or sternal fractures, pneumo- or hydrothorax, 
lung contusion, organ rupture or laceration, or embolic 
events attributable to CPR. The rate of bleeding com- 
plications was the same in both groups with regard to 
all parameters evaluated (median decrease in hemato- 
crit, lowest hematccrit, and units of red blood cells 
transfused were I 1, 3 1, and 0 in the CPR group vs 11, 
32 and 0 in the non-CPR group). Both groups also had 
a similar number of days in the cardiac care unit (me- 
dian 3) and total days hospitalized (median 9). 
DISCUSSION 
In 1980, a National Institutes of Health Consensus 
Development Conference on Thrombolytic Therapy’ 
suggested that CPR was a relative contraindication to 
thrombolytic therapy. More recently the American 
College of Cardiology/American Heart Association 
guidelines for treatment of acute myocardial infarction 
also listed CPR as a relative contraindication.2 Most 
of the major clinical trials have excluded such pa- 
tients.3*4*10-13 This question has a substantial practical 
value given the large number of patients who may 
be unnecessarily excluded from receiving the optimal 
treatment for their myocardial infarction. In our study, 
we found that 8% of the patients required some form of 
resuscitation, while another large series found a figure 
of 16%.3 
In 2 large studies cardiac arrest occurred in loo/G4 
and 1 1Y05 of patients treated with thrombolytic thera- 
py, although the use of CPR was not specified and the 
outcome in these patients was not discussed separately. 
One very early study of urokinase did report outcomes 
separately in patients who had sustained cardiac arrest: 
0 of 3 patients who had cardiac arrest before urokinase 
treatment died compared with 3 of 14 without cardiac 
arrest.14 One large study with data on this question is 
the Gruppo Italian0 per lo Studio della Streptochinasi 
Nell’lnfarto Miocardico I study, which reported sepa- 
rate data for the 3% of that population of 11,712 pa- 
tients who had primary ventricular fibrillation. Patients 
with ventricular fibrillation who received streptokinase 
had a mortality of 9% compared with 12% in similar 
patients who did not receive treatment.‘j 
In our study, the group who received CPR did not 
differ signiftcantly from the remainder of our patients 
except for a predominance of anterior myocardial in- 
farctions. As expected, the ejection fraction at the base- 
line catheterization was lower in the CPR group. It is 
not surprising that those with larger infarcts were more 
likely to sustain cardiac arrest and that mortality would 
be higher in the group requiring CPR. However, the 
significant improvement in ejection fraction seen at 7- 
day follow-up in the CPR group compared with no im- 
provement in the non-CPR group is an important fmd- 
ing. Although the increase in ejection fraction could 
represent recovery from cardiac depression resulting 
from CPR itself, this finding suggests that thrombolytic 
therapy may be particularly beneficial in this high-risk 
subgroup. We found no direct complications due to 
CPR, and in-hospital adverse events, bleeding compli- 
cations and length of hospital stay were similar in the 2 
groups. 
The potential limitations of this study are important 
to recognize. First, our study population excluded pa- 
tients with CPR of > 10 minutes and therefore no con- 
clusion can be made for that group of patients. How- 
ever, the mortality for patients requiring very prolonged 
CPR is extremely high. One study found only 5% sur- 
vival in a general population of hospitalized patients re- 
quiring > 15 minutes of resuscitation.16 Therefore, in 
such a group the additional risk of thrombolytic thera- 
py would be very small and the potential benefit large. 
Second, there is potential of P error to the extent 
that if more patients were studied we would have found 
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more complications attributable to CPR. However, the 
9.5% confidence interval for no complications is 0 to 5% 
overall and C! to 14% for patients with prolonged CPR. 
Third, we do not have data on patients who were 
eligible but not entered into the trials. There may have 
been a selection bias so that patients with complications 
from CPR were not given thrombolytic therapy. How- 
ever, our conclusions should remain valid for patients 
with apparently uncomplicated CPR. 
Finally, it may be argued that this is a retrospective 
study and that only a prospective study randomizing 
patients who have received CPR to thrombolytics or no 
thrombolytics will be able to fully resolve the issue. Al- 
though we do not have data in this study for patients 
who received CPR and did not get thrombolytics, it is 
possible that the potential benefit of therapy in this 
group is even greater than for the total population of 
patients with infarction. A previous study found 66% 
mortality in patients who had cardiac arrest early in the 
course of myocardial infarction compared with 4% in 
patients without such a complication.‘j In addition, the 
limited data from the Gruppo Italian0 per lo Studio 
della Streptochinasi Nell’Infarto Miocardico trial also 
showed a benefit of thrombolytic therapy in patients 
with cardiac arrest due to ventricular fibrillation.15 
In conclusion, this study found no adverse effect in 
giving thrombolytic therapy to patients requiring a 
short duration of CPR, suggesting that these patients 
should not be excluded from this form of treatment. 
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